1 / 18

ARMYDA-CIN Trial

ARMYDA-CIN Trial [ Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy ]. AIM : whether short-term high-dose atorvastatin load decreases the incidence of CIN after percutaneous coronary intervention (PCI).

socrates-flavian
Download Presentation

ARMYDA-CIN Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]

  2. AIM : whether short-term high-dose atorvastatin load decreases the incidence of CIN after percutaneous coronary intervention (PCI).

  3. Randomised,multicentre,prospective,double blind trial ….2 Italian institutions. INCLUSION CRITERIA Statin naïve patients with ACS(UA/NSTEMI) & a planned invasive strategy with in 48 hrs EXCLUSION CRITERIA on statin/was on statin (<3m) NSTE high risk pts needing emergency CAG (<2hrs) Baseline elevated liver enzymes (AST/ALT) LVEF<30% Renal failure with creatinine >3 mg/dl h/o renal or liver disease

  4. Procedures….standard technique All patients received aspirin (100 mg/day) and clopidogrel 600-mg load 3 hours before the procedure Nonionic low osmolar iodinated contrast agent (iobitridol,Xenetix, Guerbet)…Maximum allowable dose : body weight (kilograms) X 5ml/serum creatinine Aspirin 100 mg….indefinitely Clopidogrel 75 mg for 1 yr ALL patients … statin 40 mg after the procedure Other drugs…. Bivalirudin , GpIIbIIIainhib..

  5. Blood samples…for creatinine,CRP…before; at 24 hrs; at 48 hrs of the procedure…& after 48 hrs if clinically indicated…Peak post procedural values were taken Pre existing renal failure?(Creat>1.6/CrCl <60) … IV hydration … 1ml/kg/hr for >12hrs prior & >24 hrs post procedure.

  6. Primary end point : Incidence of CIN … post procedure rise in creat>0.5 or >25% from baseline. Secondary outcomes evaluated : Post procedure ARF (Cr rise >2mg/dl from the baseline value) Post proced levels of serum creatinine & CrCl percent variation of creatinineand CrClafter PCI versus baseline; correlation of CRP peak levels after PCI with occurrence of CIN; length of stay after PCI.

  7. RESULTS : Incidence of CIN was significantly lower in patients randomized to atorvastatin (5%, 6 of 120, vs 13.2%, 16 of 121, in placebo arm, p 0.046). Patients with CIN had received a larger contrast load versus those without CIN (240 +77 vs208 +72 ml, p 0.042). In the subgroup without baseline CRF, incidence of CIN was 1% in the atorvastatin versus 7% in the placebo group (odds ratio 0.15, 95% confidence interval 0.01 to 1.31, p 0.11) In patients with CRF, it was 14% versus 26% (odds ratio 0.48, 0.12 to 1.80, p 0.36).

  8. Postprocedurelevels of serum creatinine were significantly lower in the atorvastatin arm (1.06 + 0.35 vs1.12+ 0.27 mg/dl in placebo group, p 0.01), and CrCl was better in the drug arm (80.1+32.2 vs 72.0 +26.6 ml/min, p 0.034) After PCI percent variation of creatinine and CrClfrom baseline were also improved in the active treatment arm versus placebo (creatinine+2.4 +23.6% vs+8.2 +15.0%, p 0.024; CrCl 1.1 +19.4% vs 6.0 +12.3%,p 0.001).

  9. Length of stay after intervention was shorter in patients randomized to atorvastatin (2.9 +0.9 vs 3.2 + 0.8 days, p 0.007) and longer in patients with CIN (3.5 +0.9 vs 2.9 + 0.7 days in those without CIN, p 0.001).

  10. So….Short-term pretreatment with high-dose atorvastatin significantly decreases the occurrence of CIN in statin-naive patients with ACS receiving early PCI.

  11. STATINS : MOA : downregulatesangiotensin receptors, decreases endothelin synthesis, increasing NO bioavailability, attenuating inflammation, Decreases expression of endothelial adhesion molecules, Limiting reactive oxygen species production, protects against complement-mediated injury

  12. Previous observational study[by same group]….CIN a/w an absolute increase in cardiac events of 26% @ 4 yrs. So…..an absolute CIN decrease of 8%, as observed in ARMYDA-CIN, would translate into 8 MACEs avoided for 1,000 patients treated in 1 year.

  13. THANK YOU

More Related